Stock VPH VALEO PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Valeo Pharma Inc. Canadian Securities Exchange

Equities

VPH

CA91915B1085

Delayed Canadian Securities Exchange
Other stock markets
 03:57:37 2022-03-28 pm EDT 		5-day change 1st Jan Change
0.66 CAD -.--% Intraday chart for Valeo Pharma Inc. +1.54% -10.81%
Apr. 25 Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call
Mar. 22 Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -98% by 2026.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
VALEO PHARMA INC. Stock Valeo Pharma Inc.
-10.81% 8.29M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VPH Stock
  4. VPH Stock
  5. Ratings Valeo Pharma Inc.